Factors to watch on May 20

May 20, 2016 4:36 AM

27 0

The luxury goods group will post results for its full year to March at 0530 GMT.

The Swiss drugmaker's breast cancer drug Perjeta, or pertuzumab, has been turned down for use on Britain's state health service, making it the latest in a number of pricey new cancer treatments deemed not to offer value for money.

Also watch: Raiders' Derek Carr signs new five-year deal worth $125 million

Read more

To category page